Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).

To assess if the drugs' sensibility tested in the 3D organoids derived from biopsies could predict the clinical response (PFS) to therapy regimen for each individual ovarian cancer patient.,To assess if the drugs' sensibility tested in the 3D organoids derived from ascites fluids could predict the clinical response (PFS) to therapy regimen for each individual ovarian cancer patient.,To assess if the drugs' sensibility tested in the 3D organoids derived from biopsies could predict the clinical response (PFI) to therapy regimen for each individual ovarian cancer patient.,To assess if the drugs' sensibility tested in the 3D organoids derived from ascites fluid could predict the clinical response (PFI) to therapy regimen for each individual ovarian cancer patient.

The association of clinical, pathogenesis and mutational profile of patients affected by
 ovarian cancer have improved the armamentarium of therapies available for medical doctors.
 One of most remarkable advancements is represented by the introduction of PARP inhibitors in
 the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this
 effort and introduce novel approaches to improve the survival rate as well as predictive
 biomarkers to approved therapies. Given the absence of predictive biomarkers to standard
 therapy, patients derived organoid could be a promising platform to test clinically available
 drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model.
 The aim of this study is to correlate treatment sensibility measured in tumor derived
 organoids to clinical sensibility seen in real world patients.